- Home
- RGC vs IPHA Comparison
RGC vs IPHA Comparison
Compare RGC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- IPHA
- Stock Information
- Founded
- RGC 2014
- IPHA 1999
- Country
- RGC Hong Kong
- IPHA France
- Employees
- RGC N/A
- IPHA N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- IPHA Health Care
- Exchange
- RGC Nasdaq
- IPHA Nasdaq
- Market Cap
- RGC 171.1M
- IPHA 171.6M
- IPO Year
- RGC 2021
- IPHA 2019
- Fundamental
- Price
- RGC $6.29
- IPHA $2.25
- Analyst Decision
- RGC
- IPHA Strong Buy
- Analyst Count
- RGC 0
- IPHA 1
- Target Price
- RGC N/A
- IPHA $11.50
- AVG Volume (30 Days)
- RGC 22.5K
- IPHA 5.5K
- Earning Date
- RGC 10-25-2024
- IPHA 09-12-2024
- Dividend Yield
- RGC N/A
- IPHA N/A
- EPS Growth
- RGC N/A
- IPHA N/A
- EPS
- RGC N/A
- IPHA N/A
- Revenue
- RGC N/A
- IPHA $36,202,722.00
- Revenue This Year
- RGC N/A
- IPHA N/A
- Revenue Next Year
- RGC N/A
- IPHA $105.84
- P/E Ratio
- RGC N/A
- IPHA N/A
- Revenue Growth
- RGC N/A
- IPHA N/A
- 52 Week Low
- RGC $3.03
- IPHA $1.81
- 52 Week High
- RGC $32.44
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- RGC 45.25
- IPHA 49.51
- Support Level
- RGC $5.05
- IPHA $2.07
- Resistance Level
- RGC $7.24
- IPHA $2.29
- Average True Range (ATR)
- RGC 0.77
- IPHA 0.10
- MACD
- RGC -0.01
- IPHA -0.01
- Stochastic Oscillator
- RGC 44.08
- IPHA 52.85
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.